Inhibition of combined application of arsenic trioxide and cisplatin in the HSQ-89 cells
10.3969/j.issn.1006-5725.2014.15.006
- VernacularTitle:三氧化二砷与顺铂合用抗人口腔癌细胞株HSQ-89的实验研究
- Author:
Sui JIANG
;
Yongkang YE
;
Zhongwei CHEN
;
Can PENG
;
Chaoyang LUO
- Publication Type:Journal Article
- Keywords:
Oral cancer;
Arsenic trioxide;
Cisplatin
- From:
The Journal of Practical Medicine
2014;(15):2371-2373
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the anticancer role of arsenic trioxide (ATO) with cisplatin on human oral carcinoma HSQ-89 cells. Methods The human oral epidermoid HSQ-89 cells were chosen as the subjects. Different concentrations of ATO were added into Cisplatin(DDP)-treated cells. The inhibition rate of tumor cells was detected by MTT assay. Results Different concentrations of ATO (0,2.5,5,7.5,10,12.5 μmol/mL) were added into oral cancer HSQ-89 cells which have been treated with DDP (15 μg/mL). The inhibition rate of tumor cells were 26.9%, 67.5%, 73.0%, 88.5%, 90.4%, 98.7%respectively; The combined application of ATO with cisplatin could improve the inhibition rate of HSQ-89 cells in a dose-dependent relation. Conclusion The combined application of ATO and DDP can produce a synergistic action of inhibition on oral cancer cell.